ProQR Therapeutics (PRQR) Receivables (2022 - 2025)

ProQR Therapeutics' Receivables history runs 3 years deep, the most recent figure standing at $8.3 million for Q4 2025.

• In Q4 2025, Receivables rose 69.1% year-over-year to $8.3 million; the TTM figure through Dec 2025 stood at $8.3 million (up 69.1% YoY), while the FY2025 annual figure was $8.3 million, up 69.1% from the prior year.
• Receivables came in at $8.3 million for Q4 2025 at ProQR Therapeutics, up from $4.9 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $57.8 million in Q4 2022 to a low of $4.9 million in Q4 2024.
• A 3-year average of $23.7 million and a median of $8.3 million in 2025 frame the typical range for Receivables.
• On a YoY basis, Receivables climbed as much as 69.1% in 2025 and fell as far as 69.1% in 2025.
• ProQR Therapeutics' Receivables stood at $57.8 million in 2022, then slumped by 91.53% to $4.9 million in 2024, then soared by 69.1% to $8.3 million in 2025.
• According to Business Quant data, Receivables over the past three periods registered $8.3 million, $4.9 million, and $57.8 million for Q4 2025, Q4 2024, and Q4 2022 respectively.

Peer Comparison